

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 October 2003 (16.10.2003)

PCT

(10) International Publication Number
WO 03/084958 A1(51) International Patent Classification⁷: C07D 473/40

Research Laboratories, 1-21, Utajima 3-chome, Nishiyodogawa-ku, Osaka-shi, Osaka 555-0021 (JP).

(21) International Application Number: PCT/JP03/04259

(74) Agent: TAKASHIMA, Hajime; Fujimura Yamato Seimei Bldg., 2-14, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0044 (JP).

(22) International Filing Date: 3 April 2003 (03.04.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

— with international search report

(30) Priority Data: 2002-102456 4 April 2002 (04.04.2002) JP

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(71) Applicant (for all designated States except US): SUMIKA

FINE CHEMICALS CO., LTD. [JP/JP]; 1-21, Utajima 3-chome, Nishiyodogawa-ku, Osaka-shi, Osaka 555-0021 (JP).


(72) Inventors; and

(75) Inventors/Applicants (for US only): HAYASHI, Taketo [JP/JP]; c/o SUMIKA FINE CHEMICALS CO., LTD. Central Research Laboratories, 1-21, Utajima 3-chome, Nishiyodogawa-ku, Osaka-shi, Osaka 555-0021 (JP). KUMAZAWA, Hiroharu [JP/JP]; c/o SUMIKA FINE CHEMICALS CO., LTD. Central Research Laboratories, 1-21, Utajima 3-chome, Nishiyodogawa-ku, Osaka-shi, Osaka 555-0021 (JP). KAWAKAMI, Takehiko [JP/JP]; c/o SUMIKA FINE CHEMICALS CO., LTD. Central Research Laboratories, 1-21, Utajima 3-chome, Nishiyodogawa-ku, Osaka-shi, Osaka 555-0021 (JP).


(54) Title: PRODUCTION METHOD OF 2,6-DIHALOPURINE



[Ia]



[Ib]



[II]

WO 03/084958 A1

(57) Abstract: By reacting the compound of the formula [Ia] or [Ib] with halosilane compound and an agent for diazo reaction, 2,6-dihalopurine of the formula [II] can be produced conveniently in a high yield and can be easily isolated. wherein each symbol is as defined in the specification.

DESCRIPTION


PRODUCTION METHOD OF 2,6-DIHALOPURINE

Technical Field

The present invention relates to a production method of 2,6-dihalopurine. More particularly, the present invention relates to a production method of 2,6-dihalopurine, which is useful as a starting material for a nucleoside analog and the like useful as a pharmaceutical product.

Background Art

There are various production methods of 2,6-dihalopurine of the formula




wherein X¹ and X² are the same or different and each is halogen atom. Known methods include, for example, (A) a method comprising chlorination of xanthine with pyrophosphoryl chloride (Journal of American Chemical Society, 78, 3508-10 (1956)), (B) a method comprising chlorination of N-oxide of hipoxanthine or 6-chloropurine with phosphorus oxychloride (JP-B-45-11508, US Patent No. 3,314,938), (C) a production method comprising 4 steps using barbituric acid derivative as a starting material (Journal of Organic Chemistry, 19, 930 (1954), Journal of American Chemical Society, 80, 404-8 (1958)), (D) a production method comprising cyclization of 2,4-dichloro-5,6-diaminopyrimidine (US Patent No. 2,844,576) and the like.

However, the aforementioned method (A) is associated with defects in that it requires preparation of pyrophosphoryl chloride as a chlorinating agent from phosphorus oxychloride by a complicated method, as well as a high reaction temperature of 165°C, the use of a corrosion resistant reaction container for the reaction and a long reaction time of about 19 hours. The


aforementioned methods (A) - (D) are all defective in that they require long steps and complicated manipulations.

In addition, use of a method using a starting material, wherein the 9-position of the purine ring is alkylated, has
5 been considered, and the following reaction was reported in, for example, J. Chem. Soc., Perkin Trans. 1, 1999, 3469-3475



In this reaction, chlorotrimethylsilane and isoamyl nitrite were used in dichloromethane to give dichloropurine derivative,
10 wherein the 9-position of the purine ring was alkylated, in a yield of 61%.

Furthermore, J. Chem. Soc., Perkin Trans. 1, 1989, 2207-2213 reports the following reaction



15 In this reaction, isoamyl nitrite was used in carbon tetrachloride to give dichloropurine derivative, wherein the 9-position of the purine ring was alkylated, in a low yield of 40%. To obtain the objective 2,6-dihalopurine, wherein the 9-position is unsubstituted, the alkyl group at the 9-position
20 needs to be removed. However, there is no known method for this end, and conversion to 2,6-dihalopurine, wherein the 9-position is unsubstituted, is difficult. Thus, this method is not a preferable one.


In view of the above, the development of a convenient

production method to afford the objective 2,6-dihalopurine in a high yield is desired, which allows easy isolation thereof.


It is therefore an object of the present invention to provide a method for conveniently producing the objective 2,6-dihalopurine in a high yield, which allows easy isolation thereof.

Disclosure of the Invention

As a result of the intensive studies in an attempt to achieve the above-mentioned object, it has been found that, by reacting a compound of the formula [Ia] or [Ib]




[Ia]



[Ib]

wherein X¹ is a halogen atom and R is a hydrogen atom or acyl group (hereinafter both to be abbreviated as compound [I] unless particularly specified) with halosilane compound and an agent for diazo reaction, 2,6-dihalopurine of the formula [II]



[II]

wherein X¹ and X² are the same or different and each is a halogen atom (hereinafter to be abbreviated as 2,6-dihalopurine) can be produced conveniently in a high yield, and that the objective product can be isolated easily.

Accordingly, the present invention provides the following.

(1) A production method of 2,6-dihalopurine, which comprises

reacting compound [I] with a halosilane compound and an agent for diazo reaction.

(2) The production method of the above-mentioned (1), wherein the agent for diazo reaction is a nitrite ester.

5 (3) The production method of the above-mentioned (2), wherein the nitrite ester is isoamyl nitrite.

(4) The production method of the above-mentioned (1), wherein the reaction is carried out in the presence of a quarternary ammonium salt.

10 (5) The production method of the above-mentioned (4), wherein the quarternary ammonium salt is tetraethylammonium chloride or benzyltriethylammonium chloride.

(6) The production method of the above-mentioned (1), wherein R is an acyl group.

15 (7) The production method of the above-mentioned (6), wherein the acyl group for R is acetyl group.

(8) The production method of the above-mentioned (1), wherein the halosilane compound is chlorotrimethylsilane or dichlorodimethylsilane.

20 (9) The production method of the above-mentioned (1), wherein the halosilane compound is bromotrimethylsilane.

(10) The production method of the above-mentioned (1), wherein, after introducing an acyl group into the 9-position or the 7-position of compound [I], wherein R is a hydrogen atom, the

25 obtained compound [I], wherein R is acyl group, is reacted with halosilane compound and the agent for diazo reaction.

Detailed Description of the Invention

The 2,6-dihalopurine of the present invention encompasses tautomer.

30 The "acyl group" for R is a group represented by $-\text{C}(=\text{O})-\text{R}'$ wherein R' means, for example, a hydrocarbon group. The hydrocarbon group includes linear, branched chain or cyclic ones, which may be aliphatic or aromatic. Preferable acyl

group includes alkylcarbonyl group having 2 to 6 carbon atoms (e.g., acetyl group, propionyl group, butanoyl group and the like), benzoyl group and the like. From the aspect of improvement in reactivity and economical aspect, acetyl group is particularly preferable. Since the acetyl group can be characteristically released easily by hydrolysis, compound [I], wherein R is acetyl group, can be easily converted to 2,6-dihalopurine.

The "halogen atom" for X^1 and X^2 is fluorine atom, chlorine atom, bromine atom or iodine atom, and X^1 and X^2 may be the same or different halogen atom.

The present invention is explained in detail in the following.

By a method comprising step for reacting compound [I] with halosilane compound and an agent for diazo reaction, 2,6-dihalopurine can be produced conveniently in a high yield, and the obtained 2,6-dihalopurine can be easily isolated. The R in compound [I] is preferably an acyl group, particularly preferably an acetyl group from the reactivity and releasability. In addition, this reaction in the presence of a phase transfer catalyst preferably accelerates the reaction rate. As the phase transfer catalyst in the present invention, for example, quarternary ammonium salt, crown ether (e.g., 12-crown-4, 15-crown-5, 18-crown-6 etc.), alkyl sulfate (e.g., sodium octylsulfate etc.), alkyl sulfonate (e.g., sodium octylsulfonate etc.) and the like can be included, with preference given to quarternary ammonium salt. The amount of the phase transfer catalyst to be used is a 0.005 - 0.2 molar amount, preferably 0.01 - 0.1 molar amount, per 1 mol of compound [I].

The "quarternary ammonium salt" in the present invention is not particularly limited, and, for example, tetraethylammonium chloride, benzyltriethylammonium chloride,

trioctylmethylammonium chloride, benzyltrimethylammonium chloride and the like can be used, with preference given to tetraethylammonium chloride and benzyltriethylammonium chloride. When a quaternary ammonium salt is used, the use of a catalyst amount of, for example, 0.01 - 1 mol, preferably 0.05 - 0.1 mol, per 1 mol of compound [I] is sufficient.

In the halosilane compound to be used in the present invention, at least one halogen atom is bonded to silicon atom, or alkyl group may be bonded besides the halogen atom.

Examples thereof include trialkylhalosilane, dialkyldihalosilane, monoalkyltrihalosilane and tetrahalosilane. The alkyl group here is a linear or branched chain alkyl group having 1 to 4, preferably 1 or 2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like. The halogen atom here includes fluorine atom, chlorine atom, bromine atom and iodine atom.

Specific examples of the halosilane compound include chlorotrimethylsilane, dichlorodimethylsilane, trichloromethylsilane, tetrachlorosilane, bromotrimethylsilane and the like. Preferred are chlorotrimethylsilane, dichlorodimethylsilane and bromotrimethylsilane, and particularly preferred are chlorotrimethylsilane and dichlorodimethylsilane. The halosilane compound can be also used as a reaction solvent. The amount of use thereof is 1.5 - 30 mol, preferably 8 - 20 mol, per 1 mol of compound [I]. It is needless to say, when an organic solvent other than halosilane compound is used as a reaction solvent, the amount of halosilane compound to be used can be reduced from the above-mentioned range. The amount of halosilane compound to be used is 1 - 10 mol, preferably 1.5 - 6 mol, per 1 mol of compound [I].

As the agent for diazo reaction in the present invention, for example, nitrite ester, nitrosyl chloride, nitrosyl sulfate,

nitrogen oxide, nitrite salt (e.g., sodium nitrite, potassium nitrite and the like), and the like can be used, with preference given to nitrite ester. As the nitrite ester, for example, C₁₋₅ alkyl nitrite (e.g., methyl nitrite, ethyl nitrite, propyl nitrite, isobutyl nitrite, tert-butyl nitrite, isoamyl nitrite and the like) and the like. Of these, isoamyl nitrite is preferable. The amount of the agent for diazo reaction to be used is 1 - 3 mol, preferably 1.1 - 1.5 mol, per 1 mol of compound [I].

The reaction of the present invention can be carried out in an organic solvent, and the organic solvent to be used is not particularly limited. From the aspects of reaction rate and suppression of by-product, hydrocarbon solvents such as hexane, heptane and the like, halogenated solvents such as monochlorobenzene, dichlorobenzene and the like, and tetrahydrofuran are preferable. Of these, the hydrocarbon solvents such as hexane, heptane and the like, or halogenated solvents such as monochlorobenzene, dichlorobenzene and the like are more preferable. The amount of the organic solvent to be used is 1 - 100 ml, preferably 2 - 10 ml, per 1 g of compound [I].

The reaction of compound [I] with halosilane compound and an agent for diazo reaction completes at generally 0 - 60°C, preferably 20 - 60°C, for generally 5 - 20 hr.

When R is acyl group, 2,6-dihalopurine can be obtained by adjusting the pH of the reaction mixture to 2 - 5, preferably 4 - 5, after the completion of the reaction. As a method for adjusting the pH of the reaction mixture, for example, a method comprising addition of an aqueous alkali solution (e.g., aqueous sodium hydroxide solution etc.) to the reaction mixture, a method comprising addition of an aqueous alkali solution to the reaction mixture and addition of an aqueous acidic solution (e.g., hydrochloric acid etc.) and the like can be mentioned.

The obtained 2,6-dihalopurine can be isolated and purified by a conventional method. For example, the obtained reaction mixture is cooled, and the precipitated crystals are collected by filtration and dried. The collected crystals are 5 washed or recrystallized to give crystals having a higher purity.

The obtained 2,6-dihalopurine can be converted to a nucleoside analog useful as a pharmaceutical product according to the method described in, for example, EP656,778.

10 The compound [I] as the starting material can be obtained by the following method.

The compound [I] wherein R is hydrogen atom is commercially available and a commercially available one can be used for the reaction. It is needless to say that one produced 15 by a known method (e.g., EP543,095 etc.) can be used.

The compound [I] wherein R is acyl group can be obtained by, for example, introducing an acyl group into the 7-position or 9-position of compound [I], wherein R is hydrogen atom, according to a conventional method. An acyl group can be 20 generally introduced in the same manner as the protection of amino group with acyl group. For example, compound [I] wherein R is hydrogen atom is reacted with R'-C(=O)OH wherein R' is a hydrocarbon group defined above, or a reactive derivative thereof (e.g., ester, acid halide, acid anhydride etc.) to give 25 compound [I] wherein R is acyl group.

The introduction of acyl group is explained in the following.

When compound [I] wherein R is hydrogen atom is reacted with acid halide, a base is preferably co-used from the aspect 30 of improved reactivity and economical aspect. Examples of the base include organic base (e.g., triethylamine and the like), and inorganic base (e.g., carbonate, hydrogencarbonate and the like). The amount of the base to be used is 1 - 3 mol,

preferably 1.1 - 2 mol, per 1 mol of compound [I] wherein R is hydrogen atom.

The amount of $R'-C(=O)OH$ and a reactive derivative thereof to be used for introduction of acyl group is generally 5 1 - 3 mol, preferably 1.1 - 2 mol, per 1 mol of compound [I] wherein R is hydrogen atom.

The acyl group can be introduced without a solvent or in an organic solvent, and the introduction without a solvent is economical and convenient because the solvent does not need to 10 be evaporated. When it is introduced in an organic solvent, as the organic solvent, the same solvent as the organic solvent used for the above-mentioned reaction of compound [I] with halosilane compound and an agent for diazo reaction can be used. Other than that, N,N-dimethylacetamide, tetrahydrofuran, ethyl 15 acetate and the like can be used. From the aspect of reactivity, the use of N,N-dimethylacetamide is preferable. The use of the same solvent as the organic solvent used for the above-mentioned reaction of compound [I] with halosilane compound and an agent for diazo reaction is preferable, because 20 the solvent does not need to be evaporated and, after the formation of compound [I], compound [I] can be reacted with halosilane compound and an agent for diazo reaction in one pot without isolation. When the reaction is carried out in an organic solvent, the amount of the organic solvent to be used 25 is 1 - 20 parts by weight, preferably 2 - 5 parts by weight, per 1 part by weight of compound [I] wherein R is hydrogen atom.

While the introduction of acyl group varies depending on the reaction conditions and the like, it is completed at generally 1 - 100°C, preferably 40 - 60°C, for generally 1 hr - 30 10 hr, preferably 3 hr - 6 hr.

Examples

The present invention is explained in detail in the following by referring to Examples. The present invention is

not limited by these examples.

Example 1

(1) **Synthesis of 9-acetyl-2-amino-6-chloropurine**

2-Amino-6-chloropurine (150 g, 0.89 mol) and acetic

5 anhydride (108 g, 1.06 mol) were added to N,N-dimethylacetamide (350 ml), and the mixture was heated to 50 - 60°C and stirred for 4 hr. The reaction mixture was cooled and filtrated. The obtained crystals were washed with isopropanol (400 ml) and dried at 80°C under reduced pressure to give 9-acetyl-2-amino-

10 6-chloropurine as a pale-yellow powder (187 g, yield 99.0%).

¹H-NMR (400MHz, DMSO-d₆) δ= 2.83(s,3H), 7.26(brs,2H), 8.55(s,1H).

¹³C-NMR (100MHz, DMSO-d₆) δ= 24.65, 124.02, 139.73, 150.09, 152.89, 160.13, 167.69.

(2) **Synthesis of 2,6-dichloropurine**

15 9-Acetyl-2-amino-6-chloropurine (0.50 g, 2.36 mmol), dichlorodimethylsilane (1.01 g, 7.80 mmol), tetraethylammonium chloride (0.025 g, 0.15 mmol) and isoamyl nitrite (0.42 g, 3.54 mmol) were added to heptane (4 ml), and the mixture was heated to 50 - 60°C and stirred for 14 hr. After the completion of

20 the reaction, the mixture was filtrated. The obtained crystals were diluted with water (4.0 ml), and the mixture was adjusted to pH 4 - 5 with a 2M aqueous sodium hydroxide solution. After aging under ice-cooling for 1 hr, the mixture was filtrated, and the obtained crystals were dried under reduced pressure at

25 80°C to give a white powder (0.31 g, yield 73.8%) of 2,6-dichloropurine.

melting point: 184-186°C

¹H-NMR (400MHz, DMSO-d₆) δ=8.74(s,1H), 14.15(s,1H).

¹³C-NMR (100MHz, DMSO-d₆) δ=128.35,147.16,150.58,155.93.

30 **Example 2**

Synthesis of 2,6-dichloropurine

9-Acetyl-2-amino-6-chloropurine (0.50 g, 2.36 mmol), tetraethylammonium chloride (0.025 g, 0.15 mmol) and isoamyl

nitrite (0.42 g, 3.54 mmol) were added to chlorotrimethylsilane (4.0 g, 36.8 mmol), and the mixture was heated to 50 - 60°C and stirred for 10 hr. After the completion of the reaction, the mixture was filtrated. The obtained crystals were diluted with 5 water (4.0 ml), and the mixture was adjusted to pH 4 - 5 with a 2M aqueous sodium hydroxide solution. After aging under ice-cooling for 1 hr, the mixture was filtrated, and the obtained crystals were dried under reduced pressure at 80°C to give 2,6-dichloropurine as a white powder (0.35 g, yield 78.3%). The 10 properties of the obtained compound were the same as in Example 1(2).

Example 3**Synthesis of 2,6-dichloropurine**

9-Acetyl-2-amino-6-chloropurine (2.50 g, 11.8 mmol), 15 dichlorodimethylsilane (4.57 g, 35.4 mmol), benzyltriethylammonium chloride (0.16 g, 0.70 mmol) and isoamyl nitrite (2.07 g, 17.7 mmol) were added to o-dichlorobenzene (10 ml), and the mixture was heated to 25 - 30°C and stirred for 8 hr. After the completion of the reaction, the mixture was 20 filtrated. The obtained crystals were diluted with water (4.0 ml), and the reaction mixture was added dropwise to 2M aqueous sodium hydroxide solution (20 ml) and partitioned. The aqueous layer was adjusted to pH 4 - 5 with 35% hydrochloric acid. After aging under ice-cooling for 1 hr, the mixture was 25 filtrated, and the obtained crystals were dried under reduced pressure at 80°C to give 2,6-dichloropurine as a white powder (1.62 g, yield 72.6%). The properties of the obtained compound were the same as in Example 1(2).

Example 4**Synthesis of 2,6-dichloropurine**

2-Amino-6-chloropurine (5.00 g, 29.5 mmol), dichlorodimethylsilane (11.42 g, 88.5 mmol), benzyltriethylammonium chloride (0.40 g, 1.8 mmol) and isoamyl

nitrite (5.18 g, 44.2 mmol) were added to heptane (25 ml), and the mixture was heated to 50 - 60°C and stirred for 17 hr. After the completion of the reaction, the mixture was filtrated. The obtained crystals were diluted with water (25 ml) and 5 adjusted to pH 4 - 5 with a 2M aqueous sodium hydroxide solution. After aging under ice-cooling for 1 hr, the mixture was filtrated, and the obtained crystals were recrystallized from methanol. The mixture was dried under reduced pressure at 60°C to give 2,6-dichloropurine as a white powder (3.68 g, 10 yield 66.1%). The properties of the obtained compound were the same as in Example 1(2).

Example 5**(1) Synthesis of 9-acetyl-2-amino-6-iodopurine**

In the same manner as in Example 1 except that 2-amino-6-15 iodopurine was used instead of 2-amino-6-chloropurine, the mixture was stirred for 15 hr. The reaction mixture was subjected to post-treatment in the same manner as in Example 1 to give 9-acetyl-2-amino-6-iodopurine as a white powder. (yield 94.6%)

20 $^1\text{H-NMR}$ (400MHz, DMSO-d₆) δ =2.82 (s,3H), 7.18 (brs,2H), 8.51 (s,1H)
 $^{13}\text{C-NMR}$ (100MHz, DMSO-d₆) δ =24.80, 124.02, 131.04, 138.82, 149.02, 159.88, 167.90

(2) Synthesis of 2-bromo-6-iodopurine

9-Acetyl-2-amino-6-iodopurine (1.44 g, 4.72 mmol), 25 bromotrimethylsilane (2.17 g, 14.2 mmol) and isoamyl nitrite (0.83 g, 5.67 mmol) were added to tetrahydrofuran (5 ml), and the mixture was stirred 20 - 25°C for 19 hr to give 2-bromo-6-iodopurine.

LC/MS (-c ESI) m/z 323, 325 (M⁻¹)

30 Example 6**Synthesis of 2-bromo-6-chloropurine**

9-Acetyl-2-amino-6-chloropurine (1.00 g, 4.72 mmol), bromotrimethylsilane (2.17 g, 14.2 mmol) and isoamyl nitrite

(0.83 g, 5.67 mmol) were added to tetrahydrofuran (5 ml), and the mixture was stirred at 20 - 25°C for 19 hr to give 2-bromo-6-chloropurine.

LC/MS (-c ESI) m/z 231, 233, 235 (M⁻¹)

5

Industrial Applicability


According to the present invention, the objective 2,6-dihalopurine can be produced conveniently in a high yield and easily isolated.

10

This application is based on patent application No. 2002-102456 filed in Japan, the contents of which are hereby incorporated by reference.


CLAIMS

1. A production method of 2,6-dihalopurine of the formula [II]




[II]

wherein X¹ and X² are the same or different and each is a
5 halogen atom, which comprises reacting a compound of the
formula [Ia] or [Ib]



[Ia]



[Ib]

wherein X¹ is a halogen atom and R is a hydrogen atom or acyl
group, with a halosilane compound and an agent for diazo
10 reaction.

2. The production method of claim 1, wherein the agent for
diazo reaction is a nitrite ester.

15 3. The production method of claim 2, wherein the nitrite ester
is isoamyl nitrite.

4. The production method of claim 1, wherein the reaction is
carried out in the presence of a quarternary ammonium salt.

20

5. The production method of claim 4, wherein the quarternary
ammonium salt is tetraethylammonium chloride or
benzyltriethylammonium chloride.

6. The production method of claim 1, wherein R is an acyl group.
7. The production method of claim 6, wherein the acyl group for
5 R is acetyl group.
8. The production method of claim 1, wherein the halosilane compound is chlorotrimethylsilane or dichlorodimethylsilane.
- 10 9. The production method of claim 1, wherein the halosilane compound is bromotrimethylsilane.
10. The production method of claim 1, wherein, after introducing an acyl group into the 9-position or the 7-position
15 of compound of the formula [Ia] or [Ib], wherein R is a hydrogen atom, the obtained compound of the formula [Ia] or [Ib], wherein R is acyl group, is reacted with halosilane compound and the agent for diazo reaction.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 03/04259A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D473/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 172 365 A (SUMIKA FINE CHEMICALS CO LTD) 16 January 2002 (2002-01-16) column 2 -column 3; claims ---	1
Y	GRAYNSKWONSSCHULTZPG: "Combinatorial synthesis of 2,9-substituted purines" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 38, no. 7, 1997, pages 1161-1164, XP002953554 ISSN: 0040-4039 page 1161, paragraph 2 ---	1
A	WO 93 15075 A (SMITHKLINE BEECHAM PLC) 5 August 1993 (1993-08-05) claims ---	1 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 July 2003

15/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 03/04259

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 684 243 A (BOEHRINGER INGELHEIM KG ; BOEHRINGER INGELHEIM INT (DE)) 29 November 1995 (1995-11-29) claims ---	1
A	EP 0 543 095 A (SUMIKA FINE CHEMICALS CO LTD) 26 May 1993 (1993-05-26) cited in the application claims ---	1
P, X	WO 02 081472 A (BARTA ISTVAN ; KAWAKAMI TAKEHIKO (JP); NISHIKAWA JUNICHI (JP); KUMA) 17 October 2002 (2002-10-17) claims -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/JP 03/04259

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
EP 1172365	A 16-01-2002	JP 2002193967 A			10-07-2002
		EP 1172365 A1			16-01-2002
		US 2002004598 A1			10-01-2002
WO 9315075	A 05-08-1993	AU 3365493 A			01-09-1993
		CA 2117435 A1			05-08-1993
		EP 0625154 A1			23-11-1994
		WO 9315075 A1			05-08-1993
		JP 7503246 T			06-04-1995
		MX 9300482 A1			29-07-1994
		NZ 246677 A			27-02-1996
		ZA 9300615 A			26-11-1993
EP 0684243	A 29-11-1995	DE 4415196 C1			27-04-1995
		CA 2148193 A1			31-10-1995
		EP 0684243 A1			29-11-1995
		JP 7300480 A			14-11-1995
EP 0543095	A 26-05-1993	AT 175967 T			15-02-1999
		AU 653052 B2			15-09-1994
		AU 2139792 A			27-05-1993
		CA 2076886 A1			23-05-1993
		DE 69228226 D1			04-03-1999
		DE 69228226 T2			08-07-1999
		DK 543095 T3			13-09-1999
		EP 0543095 A2			26-05-1993
		ES 2128332 T3			16-05-1999
		JP 3198276 B2			13-08-2001
		JP 11147886 A			02-06-1999
		JP 2900104 B2			02-06-1999
		JP 6157530 A			03-06-1994
		JP 2001226378 A			21-08-2001
		KR 156265 B1			16-11-1998
		US 5389637 A			14-02-1995
		US 5440037 A			08-08-1995
		US 5391733 A			21-02-1995
WO 02081472	A 17-10-2002	WO 02081472 A1			17-10-2002